Journal Home > Volume 16 , Issue 7
Nano Research 2023, 16(7): 9859-9872 https://doi.org/10.1007/s12274-023-5742-7
Research Article | Issue | Published: 22 May 2023

Aptamer-functionalized nanoplatforms overcoming temozolomide resistance in synergistic chemo/photothermal therapy through alleviating tumor hypoxia

Show Author's Information Yun Zeng1,3,  Linfei Zhao1,3,  Ke Li4,  Jingwen Ma5,  Dan Chen1,3,  Changhu Liu2,  Wenhua Zhan2( ),  Yonghua Zhan1,3( )
School of Life Science and Technology, Xidian University and Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, Xi’an 710126, China
Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan 750004, China
International Joint Research Center for Advanced Medical Imaging and Intelligent Diagnosis and Treatment and Xi’an Key Laboratory of Intelligent Sensing and Regulation of trans-Scale Life Information, School of Life Science and Technology, Xidian University, Xi’an 710126, China
Xi’an Key Laboratory for Prevention and Treatment of Common Aging Diseases, Translational and Research Centre for Prevention and Therapy of Chronic Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an 710021, China
Radiology Department, CT and MRI Room, Ninth Hospital of Xi’an, Xi’an 710054, China
Keywords:
liposomes, blood-brain barrier, photothermal therapy, aptamers, gliomas
Topics:
Chemotherapy Controlled drug deliveryLiposomesNanoprobesTargeted drug delivery
Cite this article:
Zeng Y, Zhao L, Li K, et al. Aptamer-functionalized nanoplatforms overcoming temozolomide resistance in synergistic chemo/photothermal therapy through alleviating tumor hypoxia. Nano Research, 2023, 16(7): 9859-9872. https://doi.org/10.1007/s12274-023-5742-7
Download citation
EndNote(RIS)
BibTeX

897

Views

124

Downloads

Citations

6

Crossref

7

WoS

7

Scopus

0

CSCD

Abstract Full text Electronic supplementary material About this article

Tumor hypoxia is intimately associated with gliomas, which represents a significant threat to human health and are resistant to the first-line chemotherapeutic drug temozolomide (TMZ) due to hypoxia. In this work, to overcome TMZ resistance in orthotopic gliomas, aptamer-functionalized liposomes are manufactured to encapsulate TMZ and photothermal agent IR780, and can cross the blood-brain barrier and actively target gliomas. It is possible to employ liposomes for both fluorescence and photoacoustic imaging simultaneously due to their stability and excellent photothermal conversion capabilities. This chemo/photothermal synergistic therapeutic effect of liposomes on gliomas is demonstrated by their abilities to target orthotopic gliomas, alleviate tumor hypoxia and consequently reverse resistance of glioma cells to TMZ, thereby extending the survival time of tumor-bearing mice, making the nanoplatforms and their synergistic chemo/photothermal therapy as a potential clinical treatment for gliomas.


menu
Abstract
Full text
Outline
Electronic supplementary material
About this article

Aptamer-functionalized nanoplatforms overcoming temozolomide resistance in synergistic chemo/photothermal therapy through alleviating tumor hypoxia

Show Author's information Yun Zeng1,3, Linfei Zhao1,3, Ke Li4, Jingwen Ma5, Dan Chen1,3, Changhu Liu2, Wenhua Zhan2( ), Yonghua Zhan1,3( )
School of Life Science and Technology, Xidian University and Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, Xi’an 710126, China
Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan 750004, China
International Joint Research Center for Advanced Medical Imaging and Intelligent Diagnosis and Treatment and Xi’an Key Laboratory of Intelligent Sensing and Regulation of trans-Scale Life Information, School of Life Science and Technology, Xidian University, Xi’an 710126, China
Xi’an Key Laboratory for Prevention and Treatment of Common Aging Diseases, Translational and Research Centre for Prevention and Therapy of Chronic Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an 710021, China
Radiology Department, CT and MRI Room, Ninth Hospital of Xi’an, Xi’an 710054, China

Abstract

Tumor hypoxia is intimately associated with gliomas, which represents a significant threat to human health and are resistant to the first-line chemotherapeutic drug temozolomide (TMZ) due to hypoxia. In this work, to overcome TMZ resistance in orthotopic gliomas, aptamer-functionalized liposomes are manufactured to encapsulate TMZ and photothermal agent IR780, and can cross the blood-brain barrier and actively target gliomas. It is possible to employ liposomes for both fluorescence and photoacoustic imaging simultaneously due to their stability and excellent photothermal conversion capabilities. This chemo/photothermal synergistic therapeutic effect of liposomes on gliomas is demonstrated by their abilities to target orthotopic gliomas, alleviate tumor hypoxia and consequently reverse resistance of glioma cells to TMZ, thereby extending the survival time of tumor-bearing mice, making the nanoplatforms and their synergistic chemo/photothermal therapy as a potential clinical treatment for gliomas.

Keywords: liposomes, blood-brain barrier, photothermal therapy, aptamers, gliomas

References(49)

[1]

Molinaro, A. M.; Taylor, J. W.; Wiencke, J. K.; Wrensch, M. R. Genetic and molecular epidemiology of adult diffuse glioma. Nat. Rev. Neurol. 2019, 15, 405–417.
DOI Google Scholar
[2]

Ostrom, Q. T.; Cote, D. J.; Ascha, M.; Kruchko, C.; Barnholtz-Sloan, J. S. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018, 4, 1254–1262.
DOI Google Scholar
[3]

Messaoudi, K.; Clavreul, A.; Lagarce, F. Toward an effective strategy in glioblastoma treatment. Part I:Resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov. Today 2015, 20, 899–905.
DOI Google Scholar
[4]

Petrenko, D.; Chubarev, V.; Syzrantsev, N.; Ismail, N.; Merkulov, V.; Sologova, S.; Grigorevskikh, E.; Smolyarchuk, E.; Alyautdin, R. Temozolomide efficacy and metabolism: The implicit relevance of nanoscale delivery systems. Molecules 2022, 27, 3507.
DOI Google Scholar
[5]

Singh, N.; Miner, A.; Hennis, L.; Mittal, S. Mechanisms of temozolomide resistance in glioblastoma-a comprehensive review. Cancer Drug Resist. 2021, 4, 17–43.
DOI Google Scholar
[6]

Wick, W.; Weller, M.; van den Bent, M.; Sanson, M.; Weiler, M.; von Deimling, A.; Plass, C.; Hegi, M.; Platten, M.; Reifenberger, G. MGMT testing-the challenges for biomarker-based glioma treatment. Nat. Rev. Neurol. 2014, 10, 372–385.
DOI Google Scholar
[7]
Yu, W.; Zhang, L. L.; Wei, Q. C.; Shao, A. W. O6-methylguanine-DNA methyltransferase (MGMT): Challenges and new opportunities in glioma chemotherapy. Front. Oncol. 2020, 9, 1547.
[8]

Quartuccio, N.; Laudicella, R.; Mapelli, P.; Guglielmo, P.; Pizzuto, D. A.; Boero, M.; Arnone, G.; Picchio, M. Hypoxia PET imaging beyond 18F-FMISO in patients with high-grade glioma: 18F-FAZA and other hypoxia radiotracers. Clin. Transl. Imaging 2020, 8, 11–20.
DOI Google Scholar
[9]

Lin, W. Z.; Wu, S. H.; Chen, X. C.; Ye, Y. L.; Weng, Y. L.; Pan, Y. H.; Chen, Z. J.; Chen, L.; Qiu, X. X.; Qiu, S. F. Characterization of hypoxia signature to evaluate the tumor immune microenvironment and predict prognosis in glioma groups. Front. Oncol. 2020, 10, 796.
DOI Google Scholar
[10]

Baguley, B. C. Multiple drug resistance mechanisms in cancer. Mol. Biotechnol. 2010, 46, 308–316.
DOI Google Scholar
[11]

Musah-Eroje, A.; Watson, S. A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia. J. Neuro-Oncol. 2019, 142, 231–240.
DOI Google Scholar
[12]

Hsieh, C. H.; Lin, Y. J.; Wu, C. P.; Lee, H. T.; Shyu, W. C.; Wang, C. C. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme. Clin. Cancer Res. 2015, 21, 460–470.
DOI Google Scholar
[13]

Tang, J. H.; Ma, Z. X.; Huang, G. H.; Xu, Q. F.; Xiang, Y.; Li, N. N.; Sidlauskas, K.; Zhang, E. E.; Lv, S. Q. Downregulation of HIF-1α sensitizes U251 glioma cells to the temozolomide (TMZ) treatment. Exp. Cell Res. 2016, 343, 148–158.
DOI Google Scholar
[14]

Ge, X.; Pan, M. H.; Wang, L.; Li, W.; Jiang, C. F.; He, J.; Abouzid, K.; Liu, L. Z.; Shi, Z. M.; Jiang, B. H. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis. Cell Death Dis. 2018, 9, 1128.
DOI Google Scholar
[15]

Bastola, S.; Pavlyukov, M. S.; Yamashita, D.; Ghosh, S.; Cho, H.; Kagaya, N.; Zhang, Z.; Minata, M.; Lee, Y.; Sadahiro, H. et al. Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. Nat. Commun. 2020, 11, 4660.
DOI Google Scholar
[16]

Wang, H.; Xue, K. F.; Yang, Y. C.; Hu, H.; Xu, J. F.; Zhang, X. In situ hypoxia-induced supramolecular perylene diimide radical anions in tumors for photothermal therapy with improved specificity. J. Am. Chem. Soc. 2022, 144, 2360–2367.
DOI Google Scholar
[17]

Liu, S.; Pan, X. T.; Liu, H. Y. Two-dimensional nanomaterials for photothermal therapy. Angew. Chem., Int. Ed. 2020, 59, 5890–5900.
DOI Google Scholar
[18]

Wang, X. W.; Wang, X. Y.; Yue, Q. F.; Xu, H. Z.; Zhong, X. Y.; Sun, L. N.; Li, G. Q.; Gong, Y. H.; Yang, N. L.; Wang, Z. H. et al. Liquid exfoliation of TiN nanodots as novel sonosensitizers for photothermal-enhanced sonodynamic therapy against cancer. Nano Today 2021, 39, 101170.
DOI Google Scholar
[19]

Zhang, C.; Xia, D. L.; Liu, J. H.; Huo, D.; Jiang, X. Q.; Hu, Y. Bypassing the immunosuppression of myeloid-derived suppressor cells by reversing tumor hypoxia using a platelet-inspired platform. Adv. Funct. Mater. 2020, 30, 2000189.
DOI Google Scholar
[20]

Fang, C.; Wang, K.; Stephen, Z. R.; Mu, Q. X.; Kievit, F. M.; Chiu, D. T.; Press, O. W.; Zhang, M. Q. Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl. Mater. Interfaces 2015, 7, 6674–6682.
DOI Google Scholar
[21]

Amarandi, R. M.; Ibanescu, A.; Carasevici, E.; Marin, L.; Dragoi, B. Liposomal-based formulations: A path from basic research to temozolomide delivery inside glioblastoma tissue. Pharmaceutics 2022, 14, 308.
DOI Google Scholar
[22]

Zhu, X. F.; Zhou, H.; Liu, Y. N.; Wen, Y. Y.; Wei, C. F.; Yu, Q. Q.; Liu, J. Transferrin/aptamer conjugated mesoporous ruthenium nanosystem for redox-controlled and targeted chemo-photodynamic therapy of glioma. Acta Biomater. 2018, 82, 143–157.
DOI Google Scholar
[23]

Zhao, J.; Liu, P. D.; Ma, J.; Li, D. D.; Yang, H. Q.; Chen, W. B.; Jiang, Y. W. Enhancement of radiosensitization by silver nanoparticles functionalized with polyethylene glycol and aptamer As1411 for glioma irradiation therapy. Int. J. Nanomedicine 2019, 14, 9483–9496.
DOI Google Scholar
[24]

Ferraris, C.; Cavalli, R.; Panciani, P. P.; Battaglia, L. Overcoming the blood-brain barrier: Successes and challenges in developing nanoparticle-mediated drug delivery systems for the treatment of brain tumours. Int. J. Nanomedicine 2020, 15, 2999–3022.
DOI Google Scholar
[25]

Yasaswi, P. S.; Shetty, K.; Yadav, K. S. Temozolomide nano enabled medicine: Promises made by the nanocarriers in glioblastoma therapy. J. Control. Release 2021, 336, 549–571.
DOI Google Scholar
[26]

Fu, W.; You, C.; Ma, L.; Li, H.; Ju, Y.; Guo, X.; Shi, S. R.; Zhang, T.; Zhou, R. H.; Lin, Y. F. Enhanced efficacy of temozolomide loaded by a tetrahedral framework DNA nanoparticle in the therapy for glioblastoma. ACS Appl. Mater. Interfaces 2019, 11, 39525–39533.
DOI Google Scholar
[27]

Mojarad-Jabali, S.; Farshbaf, M.; Walker, P. R.; Hemmati, S.; Fatahi, Y.; Zakeri-Milani, P.; Sarfraz, M.; Valizadeh, H. An update on actively targeted liposomes in advanced drug delivery to glioma. Int. J. Pharm. 2021, 602, 120645.
DOI Google Scholar
[28]

Zhang, J. C.; Xiao, X.; Zhu, J. M.; Gao, Z. Y.; Lai, X. L.; Zhu, X. G.; Mao, G. H. Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy. Int. J. Nanomedicine 2018, 13, 3039–3051.
DOI Google Scholar
[29]

Ismail, M.; Yang, W.; Li, Y. F.; Chai, T. R.; Zhang, D. Y.; Du, Q. L.; Muhammad, P.; Hanif, S.; Zheng, M.; Shi, B. Y. Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. Biomaterials 2022, 287, 121608.
DOI Google Scholar
[30]

Arcella, A.; Palchetti, S.; Digiacomo, L.; Pozzi, D.; Capriotti, A. L.; Frati, L.; Oliva, M. A.; Tsaouli, G.; Rota, R.; Screpanti, I. et al. Brain targeting by liposome-biomolecular corona boosts anticancer efficacy of temozolomide in glioblastoma cells. ACS Chem. Neurosci. 2018, 9, 3166–3174.
DOI Google Scholar
[31]

Yazdian-Robati, R.; Bayat, P.; Oroojalian, F.; Zargari, M.; Ramezani, M.; Taghdisi, S. M.; Abnous, K. Therapeutic applications of AS1411 aptamer, an update review. Int. J. Biol. Macromol. 2020, 155, 1420–1431.
DOI Google Scholar
[32]

Moosavian, S. A.; Sahebkar, A. Aptamer-functionalized liposomes for targeted cancer therapy. Cancer Lett. 2019, 448, 144–154.
DOI Google Scholar
[33]

Liao, Z. X.; Chuang, E. Y.; Lin, C. C.; Ho, Y. C.; Lin, K. J.; Cheng, P. Y.; Chen, K. J.; Wei, H. J.; Sung, H. W. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance. J. Control. Release 2015, 208, 42–51.
DOI Google Scholar
[34]

Li, L. Y.; Hou, J. J.; Liu, X. J.; Guo, Y. J.; Wu, Y.; Zhang, L. H.; Yang, Z. J. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials 2014, 35, 3840–3850.
DOI Google Scholar
[35]

Wang, H.; Zhu, Z. H.; Zhang, G. L.; Lin, F. X.; Liu, Y.; Zhang, Y.; Feng, J.; Chen, W. H.; Meng, Q.; Chen, L. K. AS1411 aptamer/hyaluronic acid-bifunctionalized microemulsion co-loading shikonin and docetaxel for enhanced antiglioma therapy. J. Pharm. Sci. 2019, 108, 3684–3694.
DOI Google Scholar
[36]

Li, M. H.; Teh, C.; Ang, C. Y.; Tan, S. Y.; Luo, Z.; Qu, Q. Y.; Zhang, Y. Y.; Korzh, V.; Zhao, Y. L. Near-infrared light-absorptive stealth liposomes for localized photothermal ablation of tumors combined with chemotherapy. Adv. Funct. Mater. 2015, 25, 5602–5610.
DOI Google Scholar
[37]

Guha, S.; Shaw, S. K.; Spence, G. T.; Roland, F. M.; Smith, B. D. Clean photothermal heating and controlled release from near-infrared dye doped nanoparticles without oxygen photosensitization. Langmuir 2015, 31, 7826–7834.
DOI Google Scholar
[38]

Yin, N.; Wang, Y. H.; Huang, Y.; Cao, Y.; Jin, L. H.; Liu, J. H.; Zhang, T. Q.; Song, S. Y.; Liu, X. G.; Zhang, H. J. Modulating nanozyme-based nanomachines via microenvironmental feedback for differential photothermal therapy of orthotopic gliomas. Adv. Sci. 2023, 10, 2204937.
DOI Google Scholar
[39]

Yu, Y. W.; Wang, A. P.; Wang, S. Q.; Sun, Y. C.; Chu, L. X.; Zhou, L.; Yang, X. Y.; Liu, X. C.; Sha, C. J.; Sun, K. X. et al. Efficacy of temozolomide-conjugated gold nanoparticle photothermal therapy of drug-resistant glioblastoma and its mechanism study. Mol. Pharmaceut. 2022, 19, 1219–1229.
DOI Google Scholar
[40]

Porciani, D.; Signore, G.; Marchetti, L.; Mereghetti, P.; Nifosì, R.; Beltram, F. Two interconvertible folds modulate the activity of a DNA aptamer against transferrin receptor. Mol. Ther. Nucleic Acids 2014, 3, e144.
DOI Google Scholar
[41]

Nordling-David, M. M.; Yaffe, R.; Guez, D.; Meirow, H.; Last, D.; Grad, E.; Salomon, S.; Sharabi, S.; Levi-Kalisman, Y.; Golomb, G. et al. Liposomal temozolomide drug delivery using convection enhanced delivery. J. Control. Release 2017, 261, 138–146.
DOI Google Scholar
[42]

Fan, K. L.; Jia, X. H.; Zhou, M.; Wang, K.; Conde, J.; He, J. Y.; Tian, J.; Yan, X. Y. Ferritin nanocarrier traverses the blood brain barrier and kills glioma. ACS Nano 2018, 12, 4105–4115.
DOI Google Scholar
[43]

Fu, J. L.; Liu, M. H.; Liu, Y.; Woodbury, N. W.; Yan, H. Interenzyme substrate diffusion for an enzyme cascade organized on spatially addressable DNA nanostructures. J. Am. Chem. Soc. 2012, 134, 5516–5519.
DOI Google Scholar
[44]

Luo, S. Y.; Wang, Y.; Shen, S. H.; Tang, P.; Liu, Z. Y.; Zhang, S.; Wu, D. C. IR780-loaded hyaluronic acid@gossypol-Fe(III)-EGCG infinite coordination polymer nanoparticles for highly efficient tumor photothermal/coordinated dual drugs synergistic therapy. Adv. Funct. Mater. 2021, 31, 2100954.
DOI Google Scholar
[45]

Kanzawa, T.; Germano, I. M.; Kondo, Y.; Ito, H.; Kyo, S.; Kondo, S. Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br. J. Cancer 2003, 89, 922–929.
DOI Google Scholar
[46]

Chakravarti, A.; Erkkinen, M. G.; Nestler, U.; Stupp, R.; Mehta, M.; Aldape, K.; Gilbert, M. R.; Black, P. M.; Loeffler, J. S. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin. Cancer Res. 2006, 12, 4738–4746.
DOI Google Scholar
[47]

Zuo, H. Q.; Tao, J. X.; Shi, H.; He, J.; Zhou, Z. Y.; Zhang, C. Platelet-mimicking nanoparticles co-loaded with W18O49 and metformin alleviate tumor hypoxia for enhanced photodynamic therapy and photothermal therapy. Acta Biomater. 2018, 80, 296–307.
DOI Google Scholar
[48]

Zou, Y.; Wang, Y. B.; Xu, S.; Liu, Y. J.; Yin, J. L.; Lovejoy, D. B.; Zheng, M.; Liang, X. J.; Park, J. B.; Efremov, Y. M. et al. Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy. Adv. Mater. 2022, 34, 2203958.
DOI Google Scholar
[49]
Hu, D. H.; Sheng, Z. H.; Zhu, M. T.; Wang, X. B.; Yan, F.; Liu, C. B.; Song, L.; Qian, M.; Liu, X.; Zheng, H. R. Förster resonance energy transfer-based dual-modal theranostic nanoprobe for in situ visualization of cancer photothermal therapy. Theranostics 2018, 8, 410–422.
File
12274_2023_5742_MOESM1_ESM.pdf (2.4 MB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 02 January 2023
Revised: 11 April 2023
Accepted: 14 April 2023
Published: 22 May 2023
Issue date: July 2023

Copyright

© Tsinghua University Press 2023

Acknowledgements

Acknowledgements

This work was supported, in part, by the National Natural Science Foundation of China (Nos. 32171173, 32001074, and 82260473), the Key Research and Development Program in Ningxia Province of China (No. 2022BEG03080), the Natural Science Basic Research Plan in Ningxia Province of China (No. 2022AAC03522), the Health Commission of Ningxia Hui Autonomous Region Science and Technology Support Project for Quality Development of Medical Institutions (No. 2023-NWKYT-019), the State Key Laboratory Grant of Space Medicine Fundamentals and Application (No. SMFA20A02), the Natural Science Basic Research Key Program of Shaanxi Province (No. 2023-JC-ZD-53), the Natural Science Basic Research Plan in Shaanxi Province of China (No. 2022JQ-201), the Fundamental Research Funds for the Central Universities (Nos. ZYTS23190 and xzy012022134), and the Beijing Xisike Clinical Oncology Research Foundation.

Return